Q-omics provides the consensus-scored MTND4LP30 profile across patient tissues and cancer cell-line models. MTND4LP30 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTND4LP30 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, MTND4LP30 RNA expression shows 14,970 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where MTND4LP30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND4LP30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND4LP30 survival associations across molecular data types. MTND4LP30 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND4LP30 RNA expression–survival associations across cancer types. High MTND4LP30 expression shows unfavorable associations in LUAD, MESO and UCEC, but favorable associations in ACC, CESC and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTND4LP30 RNA expression.
This table summarizes MTND4LP30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MTND4LP30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND4LP30 shows lower tumor expression in KIRC, KIRP and LIHC and higher tumor expression in KICH and PRAD. The KICH box plot shows higher MTND4LP30 RNA expression in tumor versus normal tissue (log2 FC = +1.107, t-test p < 0.001).
This table shows molecular features associated with MTND4LP30 in patient tissues and cancer cell lines. In patient samples, MTND4LP30 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
